Tiburio is Cydan’s third orphan drug company, launched in January of 2019 with $31M in financing. Tiburio is a clinical stage biopharmaceutical company dedicated to…
Tiburio advances novel treatments for rare neuroendocrine tumors and rare endocrine diseases.
Tiburio is Cydan’s third orphan drug company, launched in January of 2019 with $31M in financing. Tiburio is a clinical stage biopharmaceutical company dedicated to…